➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Harvard Business School
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for RAF-265


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug RAF-265?

RAF-265 is an investigational drug.

There have been 237 clinical trials for RAF-265. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bayer, and Novartis Pharmaceuticals.

There are three hundred and sixty-five US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for RAF-265
TitleSponsorPhase
A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.Deciphera Pharmaceuticals LLCPhase 1
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade GliomaPacific Pediatric Neuro-Oncology ConsortiumPhase 2
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade GliomaDay One Biopharmaceuticals, Inc.Phase 2

See all RAF-265 clinical trials

Clinical Trial Summary for RAF-265

Top disease conditions for RAF-265
Top clinical trial sponsors for RAF-265

See all RAF-265 clinical trials

US Patents for RAF-265

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RAF-265   Get Started Free Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Get Started Free
RAF-265   Get Started Free Small molecule HSP70 inhibitors The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA)   Get Started Free
RAF-265   Get Started Free Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH)   Get Started Free
RAF-265   Get Started Free Methods for treatment of melanoma CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RAF-265

Drugname Country Document Number Estimated Expiration Related US Patent
RAF-265 Australia AU2014348657 2033-11-13   Get Started Free
RAF-265 Australia AU2017245411 2033-11-13   Get Started Free
RAF-265 Australia AU2019246853 2033-11-13   Get Started Free
RAF-265 Brazil BR112016010716 2033-11-13   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Moodys
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.